A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALS
A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALS
Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthood. Muscle weakness gradually progresses. Approximately 50% of patients die within 3 years after onset of symptoms, usually as the result of respiratory failure. To date, only one drug, i.e. riluzole, has proven to extend survival in patients with ALS, but only by approximately 3 to 6 months. MedDRA version: 9.1;Level: LLT;Classification code 10052889;Term: ALS Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor ...